Cathie Wood's ARK shifts focus, buys AACT stock, sells ROKU and TEM

Cathie Wood's ARK ETFs executed significant portfolio adjustments, notably selling $4.64 million in ROKU shares and $5.35 million in TEMPUS AI, signaling bearish shifts and strategic pivots away from these holdings. Concurrently, ARK increased its position in ARES ACQUISITION CORP II (AACT) with a $0.97 million purchase, and continued accumulating ARCTURUS THERAPEUTICS (ARCT) and PONY AI, indicating growing conviction in these companies within its disruptive innovation strategy.

Analysis

ARK Invest executed significant portfolio rebalancing, indicating clear shifts in conviction. The most substantial moves were divestments, with the fund selling $5.35 million of TEMPUS AI INC (TEM) and $4.64 million of ROKU INC (ROKU) through its ARKK ETF. These sales are not isolated events but part of a sustained selling trend over the past week, signaling a deliberate strategic pivot away from Tempus AI and a bearish shift on Roku. Conversely, ARK is actively building positions in other names. The fund acquired an additional $970,618 in ARES ACQUISITION CORPORATION II (AACT) via its ARKQ ETF, marking a consecutive daily purchase and suggesting growing interest. Furthermore, ARK continued its accumulation strategy in the biotech and autonomous vehicle sectors, adding $594,560 worth of ARCTURUS THERAPEUTICS (ARCT) and $74,571 of PONY AI INC (PONY), reinforcing its bullish stance on these specific disruptive technology companies.

Key Decisions for Investors

• Investors should view the continued, large-scale selling of ROKU and TEMPUS AI as a significant red flag from a high-profile growth investor, warranting a review of positions in these stocks.
• The consistent accumulation in ARES ACQUISITION CORP II, ARCTURUS THERAPEUTICS, and PONY AI indicates strengthening conviction and could signal these as ARK's next focus areas for capital deployment.
• Given the divergence in ARK's strategy, traders following the fund's flows should consider the clear rotation out of recently underperforming tech and into new or existing positions in SPACs, biotech, and private autonomous vehicle technology.